河北医科大学学报 ›› 2020, Vol. 41 ›› Issue (12): 1397-1400.doi: 10.3969/j.issn.1007-3205.2020.12.008

• • 上一篇    下一篇

肾康注射液对糖尿病肾病患者肾功能及血清TNF-α、MCP-1、IL-6的影响

  

  1. 1.河北省唐山市人民医院肾内科，河北 唐山 063001；2.河北省唐山市丰润区人民医院肾内科，
    河北 唐山 064000；3. 河北省石家庄市第五医院感染科，河北 石家庄 050000
  • 出版日期:2020-12-25 发布日期:2020-12-31
  • 作者简介:何立芳（1981-），女，河北唐山人，河北省唐山市人民医院副主任医师，医学硕士，从事肾脏疾病诊治研究。
  • 基金资助:
    河北省医学科学研究重点课题（20181398）

Effect of Shenkang injection on renal function and serum TNF-α, MCP-1, IL-6 in patients with diabetic nephropathy

  1. 1.Department of Nephrology， Tangshan People′s Hospital, Hebei Province， Tangshan 063001， China； 
    2.Department of Nephrology， Tangshan FengRun People′s Hospital, Hebei Province，Tangshan 
    064000，China; 3.Department of Infectious Disease， the Fifth Hospital of Shijiazhuang, 
    Hebei Province， Shijiazhuang 050000， China
  • Online:2020-12-25 Published:2020-12-31

HTML

PDF (PC)

168

摘要： 目的 探讨肾康注射液对糖尿病肾病患者肾功能及血清肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)、单核细胞趋化蛋白1(monocyte chemoattractant protein-1,MCP-1)、白细胞介素6（interleukin-6,IL-6）的影响。
方法 选取2型糖尿病合并肾病患者160例作为研究对象，采用随机数字表法分为对照组和观察组各80例，2组均接受常规治疗。对照组采用缬沙坦治疗，观察组在对照组基础上加用肾康注射液治疗，2组均治疗4周。比较2组治疗前后24 h尿蛋白定量（24-hour urinary protein quantification,UTP）、血肌酐(serum creatinine,SCr)、胱抑素C(Cystatin C)、血钾及血清TNF-α、MCP-1、IL-6水平。
结果 治疗后，2组患者UTP、SCr、Cystatin C及血清TNF-α、MCP-1、IL-6水平均明显低于治疗前，且观察组UTP、SCr、Cystatin C及血清TNF-α、MCP-1、IL-6水平均低于对照组，差异有统计学意义（P＜0.05），治疗前后2组血钾水平差异无统计学意义（P＞0.05）。
结论 肾康注射液可以有效降低糖尿病肾病患者UTP、SCr、Cystatin C水平，其机制可能是通过降低血清TNF-α、MCP-1、IL-6水平抑制炎症反应，发挥肾保护作用。


关键词: 糖尿病肾病, 肾康注射液, 蛋白尿, 血肌酐

Abstract: Objective To investigate the effect of Shenkang injection on renal function and serum levels of Tumor necrosis factor-α(TNF-α), Monocyte chemoattractant protein-1(MCP-1), interleukin-6(IL-6) in patients with diabetic nephropathy. 
Methods A total of 160 patients with diabetic nephropathy were randomly divided into control group(n=80) and observation group(n=80). The control group was treated with valsartan 80 mg once a day, and the observation group was treated with Shenkang injection once a day on the basis of the control group, both groups were treated for 4 weeks. The 24-hour urinary protein quantification(UTP), serum creatinine(SCr), cystatin C(Cystatin C), plasma potassium, TNF-α, MCP-1 and IL-6 levels were compared between two groups before and after treatment. 
Results After treatment, the levels of UTP, SCr, Cystatin C and serum TNF-α, MCP-1 and IL-6 in two groups were significantly lower than those before treatment, and all indexes in the observation group were significantly lower than those in the control group（P＜0.05）. There was no significant difference in plasma potassium before and after treatment(P＞0.05). 
Conclusion Shenkang injection can effectively reduce the levels of proteinuria, serum creatinine and cystatin C in patients with diabetic nephropathy, and its mechanism may be through reducing the levels of serum TNF-α, MCP-1 and IL-6, inhibiting inflammatory reaction and playing a protective role in kidney.


Key words: diabetic nephropathies, shenkang injection, proteinuria, serum creatinine

版权所有 © 《河北医科大学学报》编辑部
本系统由北京玛格泰克科技发展有限公司设计开发